SGLT2 inhibitors are recommended for all T2DM patients with DKD, irrespective of glycemic control, due to their nephroprotective and cardiovascular benefits, even at eGFR levels as low as 25 mL/min/1.73 m2 [110]. Here, SLC5A2 is linked to diabetic kidney disease.